Enliven Therapeutics (NASDAQ:ELVN) Shares Down 4.9% After Insider Selling

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) fell 4.9% during mid-day trading on Tuesday following insider selling activity. The stock traded as low as $18.61 and last traded at $18.73. 40,658 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 275,231 shares. The stock had previously closed at $19.68.

Specifically, CFO Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $21.33, for a total value of $69,322.50. Following the sale, the chief financial officer now owns 23,000 shares of the company's stock, valued at approximately $490,590. The trade was a 12.38 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ELVN shares. BTIG Research initiated coverage on Enliven Therapeutics in a research note on Friday, December 13th. They issued a "buy" rating and a $42.00 price target for the company. HC Wainwright raised their target price on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the company a "buy" rating in a research note on Friday, March 21st. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $38.75.

Remove Ads

Enliven Therapeutics Stock Down 6.7 %

The stock has a market capitalization of $915.88 million, a price-to-earnings ratio of -9.84 and a beta of 1.03. The company's fifty day simple moving average is $21.03 and its 200 day simple moving average is $23.62.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.07. The firm had revenue of $0.03 million for the quarter. As a group, analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Institutional Investors Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC increased its position in Enliven Therapeutics by 230.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after acquiring an additional 1,114 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Enliven Therapeutics during the fourth quarter worth approximately $97,000. BNP Paribas Financial Markets bought a new position in shares of Enliven Therapeutics during the fourth quarter worth approximately $112,000. ExodusPoint Capital Management LP acquired a new stake in shares of Enliven Therapeutics in the fourth quarter valued at approximately $200,000. Finally, Brevan Howard Capital Management LP bought a new stake in shares of Enliven Therapeutics in the fourth quarter valued at approximately $228,000. Institutional investors and hedge funds own 95.08% of the company's stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.